Synermore Biologics
Industry
- Biotechnology
See more in Biomedtracker
Latest on Synermore Biologics
Generics Bulletin
• By Vibha Ravi
Aurobindo Pharma is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche unit Genentech and Novartis , CEO
Scrip
• By Vibha Ravi
Aurobindo Pharma Limited is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche Holding AG unit Genentech,
Scrip
• By Ayisha Sharma
Novartis AG ’s ligelizumab has underperformed in two Phase III studies despite positive analyst sentiment, shifting attentions to its other late-stage skin candidate, remibrutinib. Ligelizumab is in t